Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia

Autor: Vesa Lindström, Janne Aittoniemi, Urpu Salmenniemi, Helena Käyhty, Heini Huhtala, Marjatta Sinisalo

Publikováno v: Human Vaccines & Immunotherapeutics, Vol 15, Iss 12, Pp 2910-2913 (2019)

The 23-valent pneumococcal polysaccharide vaccine (PPV23) given alone is ineffective in patients with chronic lymphocytic leukemia (CLL) and better antibody response is achieved with pneumococcal conjugate vaccines (PCVs). In this study, we determine

Externí odkaz: https://doaj.org/article/9c1ec68a5ffa4213a8687d6a530de61b

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Autor: Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Björn Schöttker, Thomas Nösslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jäger, Maria B.L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek

Publikováno v: Eichhorst, B, Niemann, C U, Kater, A P, Fürstenau, M, von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Nösslinger, T, Janssens, A, Christiansen, I, Baumann, M, Frederiksen, H, van der Klift, M, Jäger, U, Leys, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H, Enggaard, L, Goede, J, Regelink, J C, Widmer, A, Simon, F, De Silva, N, Fink, A-M, Bahlo, J, Fischer, K, Wendtner, C-M, Kreuzer, K A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, van Oers, M, Geisler, C, Stilgenbauer, S, Hallek, M, German CLL Study Group (GCLLSG), Haemato-Oncology Foundation for Adults in the Netherlands (HOVON), Nordic CLL Study Groups, Swiss Group for Clinical Cancer Research (SAKK), The Israeli CLL Association & Cancer Trials Ireland 2023, ' First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia ', The New England Journal of Medicine, vol. 388, no. 19, pp. 1739-1754 . https://doi.org/10.1056/NEJMoa2213093

BACKGROUNDRandomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.METHODSIn a phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57065540dd32adf0cc1d031449d13807
https://vbn.aau.dk/da/publications/3cae35e7-c81b-42b3-8598-001ac74af83e

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Autor: Michael Gregor, Florian Simon, Philipp B. Staber, Anna-Maria Fink, Christof Schneider, Vesa Lindström, Matthias Ritgen, Mels Hoogendoorn, Caspar da Cunha-Bang, Tamar Tadmor, Thomas Illmer, Maria B.L. Leijs, Arnon P. Kater, Nisha De Silva, Clemens-Martin Wendtner, Can Zhang, Julia von Tresckow, Marinus H. J. van Oers, Stephan Stilgenbauer, Henrik Frederiksen, Carsten Utoft Niemann, Moritz Fürstenau, Eugen Tausch, Michael Baumann, Sandra Robrecht, Christian Bjørn Poulsen, Ann Janssens, Holger Hebart, Monika Brüggemann, Gunnar Juliusson, Karl-Anton Kreuzer, Thomas Noesslinger, Tobias Gaska, Marjolein van der Klift, Christian H. Geisler, Kourosh Lotfi, Ilse Christiansen, Barbara Eichhorst, Björn Schöttker, Harry R. Koene, Mark-David Levin, Patrick Thornton, Michael Hallek, Kirsten Fischer, Ulrich Jaeger

Publikováno v: Eichhorst, B, Niemann, C U, Kater, A P, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, C B, Thomas Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U J, Frederiksen, H, B.L. Leijs, M, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H R, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Clemens-Martin Wendtner, Kreuzer, K-A, Ritgen, M, Brüggemann, M B, Tausch, E, Levin, M-D, van Oers, M H J, Geisler, C H, Stilgenbauer, S & Hallek, M 2021, ' A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial ', Blood, vol. 138, no. Supplement 1, pp. 71 . https://doi.org/10.1182/blood-2021-146161
Eichhorst, B, Niemann, C, Kater, A P, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, Da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U, Frederiksen, H, Leijs, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H R, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Wendtner, C-M, Kreuzer, K-A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, Van Oers, M H J, Geisler, C H, Stilgenbauer, S & Hallek, M 2021, ' A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial ', Blood, vol. 138, no. Suppl. 1, 71 . https://doi.org/10.1182/blood-2021-146161

Background: For fit CLL patients (pts), continuous BTK inhibitor treatment is replacing CIT as standard of care in frontline setting, particularly in pts with unfavorable prognostic factors. The time limited combinations venetoclax plus obinutuzumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46700f17dedbd3070657cd5923f53a3a
https://portal.findresearcher.sdu.dk/da/publications/fca2ae81-daf7-4cd6-8e83-f4a2a71437b8

Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia

Autor: Helena Käyhty, Maija Itälä-Remes, Heini Huhtala, Vesa Lindström, Urpu Salmenniemi, Janne Aittoniemi, Marjatta Sinisalo

Publikováno v: Human Vaccines and Immunotherapeutics. 14(6):1-4

Patients with chronic lymphocytic leukemia (CLL) are at a high risk for infections caused by Streptococcus pneumoniae. A pneumococcal conjugate vaccine (PCV) can induce a significant antibody response for some CLL patients. In this study we investiga

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f568f8c565a4f2e7c88000fa793fa3
https://doi.org/10.1080/21645515.2018.1436424

Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia

Autor: Janne Aittoniemi, Vesa Lindström, Urpu Salmenniemi, Marjatta Sinisalo, Heini Huhtala, Helena Käyhty

Publikováno v: Hum Vaccin Immunother

The 23-valent pneumococcal polysaccharide vaccine (PPV23) given alone is ineffective in patients with chronic lymphocytic leukemia (CLL) and better antibody response is achieved with pneumococcal conjugate vaccines (PCVs). In this study, we determine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43a9d4c54cdaf9dde22fc7b3cf85be82
https://trepo.tuni.fi/handle/10024/117262